Co-Diagnostics Q2 revenues down 61%; shares down 16% after hours NASDAQ | Post-Market: $17.59-3.41 (-16.24%)7:44 PM Ingresos: $ 24.0M (-61.0%). Los ingresos se componen en gran parte de las ventas de prueba de COVID-19. Ingresos netos: $ 12.6M (+ 999%); BPA: $ 0,43 (+ 637,5%).Consumo de efectivo (6 meses): ($ 0.3M) (+ 88.9%). https://seekingalpha.com/news/3605440-co-diagnostics-q2-revenues-down-61-shares-down-16-after-hours ---------El acuerdo de $ 12.5 mil millones de Thermo Fisher para Qiagen fracasa, ya que la demanda de prueba COVID-19 ilumina un nuevo camino a seguir On heels of U.S. pact, Johnson & Johnson strikes a double-size COVID vaccine deal with EuropeRoadmap aims to help hospitals continue providing care amid surges of COVID-19 casesThermo Fisher’s $12.5B deal for Qiagen falls through, as COVID-19 test demand lights new path forwardAstraZeneca, after prior issues with FluMist, ramps up production in response to pandemicHealthcare roundup: Kroger Health launches COVID-19 testing program for employersBiopharma roundup: Novavax teams up with SK bioscience for shot antigen; J&J taps Biological E for Indian vaccine supplyHighmark’s Allegheny Health Network posts $116M in losses in first half of 2020 as volumes skid due to COVID-19 AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine dosesOne Medical plans to move into North Carolina, Wisconsin amid Q2 membership jumpsCOVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst https://www.fiercebiotech.com/medtech/thermo-fisher-s-12-5b-deal-for-qiagen-flops-as-covid-19-test-demand-lights-new-path-forward?mkt_tok=eyJpIjoiWVRCaVlURTNaR1JsWWprMSIsInQiOiJaRDB5dzhieE5hT3IzdWdsWm5pWVwvVWt6OGhUOVcxdXR0Wm45YmxGeVNDT1wvS2Y5b25LVXVkbXVFd016QUI2c0dmZ0pkZW53UlU4bnB2NThjU2ppOFdsSnl1elwvYnFXWkpHa1NaWVBmdTh0NktiaDhnNXJSaGZkR2NuajFiNW5kclNNaDEwUmRyQm8yUUpVcnlwbThBS0E9PSJ9&mrkid=122817369
USA